Tempus AI Inc (NASDAQ:TEM) shares are trading higher Monday morning after the company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD ...

KYOTO & FUJISAWA, Japan--(BUSINESS WIRE)--xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research ...

Human-based genetic editing systems — as opposed to bacteria-based editing systems like CRISPR — have less potential for issues. Photo credit: iStock Genetic editing holds promise to treat incurable ...

National University of Singapore (NUS) researchers have devised a method to safely and temporarily "switch off" and then "turn on" ribonucleic acid (RNA) inside cells. This is achieved using ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Traditional live attenuated vaccines (LAVs) ...

Wave’s treatment, WVE-006, was the first of its kind to reach human testing. WVE-006 edits RNA, the messenger molecules that turn DNA into proteins. That approach is seen as a potentially safer and ...

Life may have first emerged in deep sea thermal vents or surface hot springs (Yellowstone National Park’s Grand Prismatic Spring is shown here). New research shows how high-energy thioesters could ...

Chemists at University College London have shown how two of biology's most fundamental ingredients, RNA (ribonucleic acid) and amino acids, could have spontaneously joined together at the origin of ...

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. For fluorescence-based applications, RNA aptamers can be ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of "genetic surgery" is performed on DNA, for ...

Donidalorsen is the first RNA-targeted prophylactic treatment approved for hereditary angioedema, offering significant attack rate reduction. The OASIS-HAE study showed an 81% reduction in HAE attacks ...

We’re celebrating 180 years of Scientific American. Explore our legacy of discovery and look ahead to the future. In 1957, just four years after Francis Crick and other scientists solved the riddle of ...